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Abstract: Different hepatic and biliary tract disorders may occur with celiac disease. Some 
have been hypothesized to share genetic or immunopathogenetic factors, such as primary biliary 
cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Other hepatic changes 
in celiac disease may occur with malnutrition resulting from impaired nutrient absorption, 
including hepatic steatosis. In addition, celiac disease may be associated with rare hepatic 
complications, such as hepatic T-cell lymphoma.
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Introduction
Several hepatobiliary disorders occur in celiac disease, a genetically-based small 
bowel disorder that resolves with the complete restriction of dietary gluten.1 Almost 
three decades ago, changes in the liver were first recognized in celiac disease.2 
Later, these observations were prospectively confirmed and findings were extended 
to effects induced by treatment with a gluten-free diet.3 In some, hepatic changes 
entirely reversed after a gluten-free diet, while in others, clinically significant liver 
disease was not corrected by diet alone.3 Overall recognition of celiac disease has 
been improved in recent years, in large part related to development and application 
of modern serological assays for celiac screening.4−6 Likely, as a result, more precise 
estimates of overall liver disease burden in celiac disease will emerge. Indeed, in a 
recent extensive population-based study from Sweden, individuals with celiac disease 
were found to be at increased risk for both prior and subsequent liver disease, however, 
the risk of liver transplantation was not increased.7
If unexplained elevations of liver enzymes occur, almost 10% will prove to have 
celiac disease.8,9 In 55 patients with increased liver chemistry tests, in the absence of 
other known cause, endomysial and gliadin antibodies were examined.8 Five patients 
were sero-positive and small bowel biopsies showed changes of celiac disease that 
responded to a gluten-free diet. In a further investigation, liver biopsies revealed 
a non-specific inflammatory process and liver chemistry tests normalized with a 
gluten-free diet. In 140 patients with chronic elevation of transaminase values, gliadin 
and endomysial antibodies were positive in 13 cases.9 After one year on a gluten-free 
diet, 12 had normalization of liver enzyme tests.9
In already documented celiac disease, abnormal liver enzyme tests may also be 
present.2,10−12 Elevated liver enzymes were recorded in 30 of 75 patients, or almost 40%.2 Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Others showed increased levels in 39 of 65 children, or 
about 60%.10 Later, about 50% of celiacs had increased 
liver enzyme values.11 In some, a liver biopsy revealed an 
entirely non-specific inflammatory process although a more 
specific label of “chronic active hepatitis” was provided 
in five of 37 patients, or 13.5%. Finally, 158 consecutive 
adults with celiac disease were reported with 42% having 
abnormal liver enzyme levels. A gluten-free diet ranging 
from 1–10 years resulted in complete normalization of liver 
chemistry tests in 95%.12
Not all studies have demonstrated completely normal 
liver chemistry results after institution of a gluten-free diet 
in all patients. This may reflect, in part, the heterogeneous 
nature of celiac disease. For instance, in some, involvement 
along the length of the small bowel may be extensive, while 
in others, changes may be limited to the proximal small 
bowel alone. In some studies, different durations of exposure 
to a gluten-free diet may have been critical before liver 
chemistry tests were observed to normalize. Other factors 
may play a role. For example, Selcuk et al noted a case 
with apparent progression of liver disease from steatosis to 
steatohepatitis associated with weight gain on gluten-free 
diet, possibly related to development of a metabolic 
syndrome.13 A concomitant infection, such as hepatitis C14 
could play a role, possibly through a molecular-mimicry-like 
pathogenetic mechanism suggested for adenovirus 12 in 
celiac disease,15 but others have concluded that no clear 
  correlation is evident.16−18 Alternatively, treatment of 
  hepatitis C with interferon/ribavirin has been hypothesized 
to activate celiac disease,19 prompting some to raise the issue 
of routine screening for celiac disease prior to anti-viral 
treatment.20 Finally, celiac disease has also been detected 
after   orthotopic liver transplantation in a case of hepatitis C 
associated cirrhosis.21
Persistent abnormalities in liver chemistry tests may also 
be due to a clinically occult, but specific hepatobiliary tract 
disorder sharing common immunopathogenetic features with 
celiac disease. Examples of immune-mediated disorders 
include primary biliary cirrhosis, autoimmune (lymphocytic) 
sclerosing cholangitis, or autoimmune hepatitis. Moreover, 
in hemochromatosis, a genetically-based disorder with 
altered control of small intestinal iron absorption with con-
comitant iron overload, celiac disease has been recorded. 
In addition, chronic changes in liver chemistry tests may 
reflect a direct effect of celiac disease on the liver per se. 
For example, impaired absorption and resultant malnutrition 
may lead to abnormal hepatic fat deposition, related, in part, 
to impaired fat mobilization from hepatocytes. In fact, even 
massive hepatic steatosis has been reported in celiac disease. 
Finally, but very rarely, patients may develop a specific 
complication of celiac disease that involves the liver, such 
as malignant lymphoma, including a specific, but rare T-cell 
type, hepatosplenic lymphoma.
Primary biliary cirrhosis
In 1978, primary biliary cirrhosis was described with celiac 
disease.22 Later, additional cases were described.23−25 For 
both primary biliary cirrhosis and celiac disease, other 
concomitant immune-mediated conditions were noted, 
including diabetes and thyroiditis.25−28 In addition to reports 
from Europe and the Americas, concurrent primary biliary 
cirrhosis and celiac disease was also noted in South Asians29 
and the Coast Salish, an aboriginal population in Canada, 
believed to be of Asian descent.26 Weight loss, malabsorption, 
osteopenic bone disease, steatorrhea, and elevated alkaline 
phosphatase levels are common in both disorders. As a result, 
celiac disease and primary biliary cirrhosis may be difficult to 
recognize as two distinct disorders, especially early in their 
clinical onset. Restriction of dietary gluten may improve the 
celiac disease, but usually, abnormal liver chemistry tests 
persist suggesting that the liver disease is not affected.
More recent studies have explored serological screening 
in both diseases. Using a patient registry in the United 
Kingdom,30 the prevalence of primary biliary cirrhosis was 
defined in 143 celiac patients as 3%, while the prevalence 
of celiac disease in 67 primary biliary cirrhosis patients was 
6%. As a result, screening with antimitochrondrial antibodies 
in celiac disease was recommended, while in primary biliary 
cirrhosis, serological screening with gliadin antibodies or 
small intestinal biopsy was suggested.31 Similar findings 
of 7% of 57 primary biliary cirrhosis patients were noted 
based on initial evaluation using endomysial antibodies (11% 
positive) followed by later duodenal biopsy confirmation. 
Despite 12 to 24 months on gluten-free diets, however, 
improvement in liver chemistry tests was not detected even 
though endomysial antibodies disappeared. Using Danish 
and Swedish registry data based on over 8000 patients with 
celiac disease, an increased risk of primary biliary cirrhosis 
was also suggested.32 Later, stored sera from 378 Canadian 
patients with primary biliary cirrhosis were employed 
to screen for celiac disease in our laboratory.33 Both IgA 
antibodies to endomysium and tissue transglutaminase 
were positive in 10 patients (2.6%). Of these, five patients 
had small bowel biopsies confirming celiac disease. An 
additional 44 primary biliary cirrhosis patients had raised IgA 
tissue transglutaminase antibodies, but the same sera were Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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negative for IgA endomysium antibodies. In 255 patients with 
autoimmune cholestatic liver disorders (including 173 with 
primary biliary cirrhosis), a different investigative group34 
found nine with celiac disease (including seven in those with 
primary biliary cirrhosis, or 4%). Finally, the importance of 
biopsy confirmation in primary biliary cirrhosis was noted 
as false-positive IgA or IgG-tTG antibodies may occur in 
primary biliary cirrhosis.35,36
In a later study using a general practice longitudinal 
database from the United Kingdom,37 an overall three-fold 
risk of primary biliary cirrhosis was demonstrated in 4,732 
patients diagnosed with celiac disease compared to 23,620 
age- and sex-matched controls.
Primary sclerosing cholangitis
In 1988, primary sclerosing cholangitis was linked to celiac 
disease in three patients with diarrhea and steatorrhea.38 
Two also had concomitant “ulcerative colitis” known to 
be associated with primary sclerosing cholangitis. In these, 
hepatic and biliary tract changes were defined by liver 
biopsy and cholangiograms, but these did not respond to a 
gluten-free diet. Subsequent reports have described other 
cases.11,34,39−42 In one, the predominant lymphocytic nature 
of the portal tract inflammatory process was noted with 
increased intra-epithelial lymphocytes in biliary ductal 
epithelium,42 also noted in gastric and colonic epithelium of 
celiac patients.43,44 Another patient with sclerosing cholangitis 
in celiac disease developed a cholangiocarcinoma.45 To 
date, however, it has been difficult to confirm any definitive 
hepatobiliary tract response to a gluten-free diet. In part, 
this may reflect sampling error associated with liver biopsy 
as well as the limited specificity of liver chemistry test 
markers for cholestasis (eg, serum alkaline phosphatase). 
Indeed, the origin of serum alkaline phosphatase in this 
setting may include the hepatobiliary tract as well as other 
sources (eg, bone, intestine). Each of these sources might 
be substantially altered in celiac disease, and potentially 
improved with a gluten-free diet.
Autoimmune hepatitis  
and cholangitis
This has been noted in limited case reports and survey 
studies.46−49 Unfortunately, many appeared before hepatitis 
C testing.46,47 In one, liver biopsies were done in 37 of 171 
celiac patients and changes of “chronic active hepatitis” 
were detected in five, or 2.3%. In another survey study of 
157 patients with “type 1” autoimmune hepatitis and 24 
with “type 2” autoimmune hepatitis for celiac disease, eight 
of these 181 patients (4%) were positive for endomysial 
antibodies, including six with “type 1” disease (4%) and 
two with “type 2” disease (8%). Five of the eight patients, 
most being asymptomatic, had a duodenal biopsy and all 
showed typical changes of untreated celiac disease. Effects on 
symptoms and small bowel biopsy changes caused by drugs 
(steroids, azathioprine, or both) may have been important, 
but were not detailed. In a recent study, 47 consecutive 
patients with autoimmune hepatitis, including 39 with 
“type 1” disease and eight with “type 2” disease were 
evaluated. Anti-IgA tissue transglutaminase and endomysial 
antibodies were positive in three patients (6.4%) and small 
bowel biopsies confirmed the presence of the celiac disease 
histological changes. Finally, a recent report showed that 
celiac disease associated antibodies fell in autoimmune liver 
disease after hepatic transplantation.50
Celiac disease and other types of autoimmune liver and 
biliary tract disease may coexist. A case report of autoimmune 
cholangitis,51 a cholestatic liver disorder with biochemical 
evidence of cholestasis, histological evidence of inflammatory 
bile duct damage and an absence of antimitochondrial 
antbodies, was previously described in a patient with celiac 
disease. Interestingly, this patient’s small intestinal biopsies 
were reported to be normal without a gluten-free diet while 
being treated with steroids and azathioprine. In another case, 
hepatic blood tests were improved without necessitating use 
of immunosuppressive drugs.52
Hemochromatosis or iron  
overload liver disease
Celiac disease has been associated with hemochromatosis.53−56 
Since both are relatively common, however, any association 
could be coincidental.57 Iron absorption largely occurs in 
the proximal duodenum, the site most often histologically 
altered in celiac disease. Indeed, “isolated” iron deficiency 
with anemia may be the initial clinical manifestation of 
celiac disease. In contrast, in iron overload liver disease, 
inappropriate iron absorption from the proximal small 
intestine occurs as body iron stores are markedly increased. 
In an early study, treatment of celiac disease and improved 
small intestinal histology led to worsening liver chemisty test 
values and recognition of occult iron overload liver disease 
(C282Y-negative), thought to be related to increased intestinal 
uptake of iron. Another similar case of C282Y-positive 
hemochromatosis presented with diarrhea, positive anti-
gliadin, and endomysial antibodies. Subsequent small bowel 
biopsies showed villous atrophy. In this case, phlebotomy 
treatment was terminated early due to an unanticipated Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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rapid fall in serum ferritin. As both disorders are associated 
with the HLA-region on chromosome 6, there could be a 
genetically-based linkage. Later investigations have sought 
to resolve the possible relationship. In one report,58 HFE 
(hemochromatosis susceptibility gene) locus mutations were 
noted to be common in celiac disease, possibly for protection 
of the celiac from iron deficiency.59 A later study in an Italian 
population with untreated celiac disease found that HFE 
mutations failed to protect against the development of iron 
deficiency.60 In a case study of a patient with homozygous 
C282Y and celiac disease,61 reduced expression of the 
divalent metal transporter 1 (DMT1) was observed, but not 
ferroportin 1 (FP1) or the transferrin receptor 1 (TfR1).
Other liver disorders  
in celiac disease
Fatty liver
Common causes of hepatic steatosis in celiac disease 
could include alcohol-induced steatosis, diabetes mellitus, 
non-alcoholic fatty liver disease, and some forms of drug 
therapy including corticosteroids. In developing countries, 
dietary protein deficiency and kwashiorkor may be important 
causes. Intestinal malabsorption per se has been associated 
with hepatic steatosis after jejunoileal bypass for morbid 
obesity62,63 and sometimes in those with inflammatory bowel 
disease, particularly following extensive intestinal resec-
tions.64 Because celiac disease is now frequently recognized 
in a clinically occult form before manifestations of marked 
nutrient depletion are detected, hepatic steatosis is probably 
less common than in other intestinal diseases.
Several cases of massive fatty infiltration of the liver 
have been described in adults with celiac disease.65−68 
Clearly, lesser degrees of hepatic fat deposition may also 
occur. Most often if massive steatosis is evident, elevated 
transaminase and alkaline phosphatase activities occur along 
with alterations in coagulation. However, in most, clinical and 
biochemical changes attributed to the hepatic steatosis were 
improved with a gluten-free diet. In a patient with massive 
hepatic steatosis,67 a gluten-free diet for about one year also 
resulted in normalization of the histologically-defined fatty 
changes in the liver.
Precise mechanisms involved in fat deposition in the 
liver are poorly defined. Following jejunoileal bypass, 
reduced serum levels of some essential and nonessential 
amino acids may be observed.62,63 In addition, changes in 
serum amino acids have been recorded in patients with 
starvation-associated kwashiorkor.69,70 Based on these other 
largely nutrition-based disorders, it has been hypothesized 
that malabsorption in celiac disease might lead to chronic 
deficiency of a lipotropic factor (eg, choline). With an 
associated pyridoxine deficiency, hepatic steatosis might 
occur.71 In a recent study, increased intestinal permeability 
and altered tight junctions were documented in nonalcohol 
fatty liver disease as well as in primary biliary cirrhosis.72,73 
The changes appeared to be related, in part, to the presence 
of small intestinal bacterial overgrowth. Similar permeability 
changes occur in celiac disease,74−76 and may be a factor in 
development of liver alterations in celiac disease. Further 
studies are needed to define the pathogenesis for these liver 
changes in celiac disease.
Hepatic vein obstruction
Although mesenteric vascular ischemia77 and vasculitis78−81 
have been described in celiac disease, there are also reports 
of a unusual Budd–Chiari-like syndrome among celiac chil-
dren from North Africa, particularly Tunisian and Algeria.82,83 
Hepatic vein obstruction was also documented in three 
adults.84 Deficiencies in protein C and antithrombin III were 
detected, and malabsorption of vitamin K in celiac disease 
was proposed to cause transient protein C or protein S 
deficiencies. Further studies are needed to identify possible 
factors, either dietary or other environmental agents that may 
be critical. More recently, a celiac patient with a Budd–Chiari 
syndrome associated with membranous obstruction of the 
inferior vena cava treated successfully with percutaneous 
balloon angioplasty was reported.85
Hepatic malignancies
While hepatocellular cancer has been reported in one patient, 
cirrhosis was also present.86 Occasionally, the liver may 
be involved with lymphoma, the most frequently detected 
malignant disorder in celiac disease.87 In some, lymphomatous 
deposits have been detected in the liver, presumably as meta-
static lesions. For example, lymphoma in the liver was appar-
ently secondary to jejunal lymphoma, complicating celiac 
disease. In general, involvement of the liver in celiac disease 
patients with lymphoma is limited and overshadowed by the 
clinical course of the intestinal disease. However, in a recent 
case report, an immune reaction in the splenoportal axis was 
postulated as a cause for severe portal hypertension.88 Primary 
involvement with hepatic lymphoma may also occur. Indeed, 
a fulminant cholestatic syndrome has been described in celiac 
disease, resulting in hepatic failure.89 Later investigations 
showed widespread hepatic involvement with an unusual 
lymphoid neoplasm classified as hepatosplenic lymphoma, 
a rare peripheral T-cell lymphoma with rearrangement of the Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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gamma-delta T-cell receptor.90,91 Similar necrotizing foci in 
the liver have recently been described in celiac disease with 
lymph node cavitation.92
Liver failure
In patients from Finland with severe liver failure from 
a variety of causes in celiac disease, dietary treatment 
reversed hepatic dysfunction, even in cases where liver 
transplantation was being considered.93 In these liver disease 
patients, congenital hepatic fibrosis, massive hepatic steatosis 
and progressive hepatitis were noted. In a post-transplant 
group, 4.3% had celiac disease discovered before or after 
transplant. In this group, liver diseases recorded were 
primary biliary cirrhosis, autoimmune hepatitis, primary 
sclerosing cholangitis, and congenital hepatic fibrosis. In 
a recent report, 13 patients are noted with liver failure and 
celiac disease that had an improvement in liver function 
with a gluten-free diet.94 Causes in this report included 
primary biliary cirrhosis, primary sclerosing cholangitis, 
and chronic autoimmune hepatitis. Severe liver disease 
has also recently been described to complicate childhood 
celiac disease up to age three years.95 Among six cases, four 
presented with acute liver failure with two requiring hepatic 
transplantation, prompting the suggestion that new onset 
celiac disease in children should be evaluated for evidence of 
liver dysfunction. Finally, children with severe liver disease 
should also be investigated for untreated celiac disease.
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